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Introduction. Ewing’s sarcomas (EWSs) of bone and soft tissue are neuroectodermal tumors that aﬀect both axial and appendicular
locations. We hypothesized that axial location predicted poor outcome in EWS patients. Materials and Methods.S i x t y - s e v e n
patients (57 with bone EWS and 10 with soft tissue EWS) were identiﬁed from our database. Thirty-four (51%) had axial EWS and
33 (49%) had appendicular EWS. Statistical analyses identiﬁed predictors of poor outcome. Results and Discussion.A x i a ll o c a t i o n ,
largesize,metastasesatpresentation,lackofdeﬁnitivetreatment,andpositivesurgicalmarginsallcorrelatedwithpooroutcomein
univariate analysis. In multivariate analysis, axial location still predicted poor outcome when adjusted for pretreatment variables.
Axial location was not statistically predictive of poor outcome when adjusted for treatment variables. Conclusions. Anatomic
location has a negative eﬀect on outcome in EWS that cannot be completely explained by pretreatment or treatment factors.
Additional studies are required to determine if there is a biologic diﬀerence between axial and appendicular EWS.
1.Introduction
Ewing’s sarcoma (EWS) is a rare malignant neoplasm com-
posed of primitive neuroectodermal cells. It is most com-
monlyfoundintheskeletonandisthesecondmostcommon
primary tumor of bone. Soft tissue Ewing’s sarcoma is much
more rare, but is histologically and genetically identical to
EWS of bone and is treated similarly [1, 2]. The mainstays of
modern treatment for EWS include chemotherapy, surgery,
and radiation therapy (XRT). With current treatment strate-
gies, overall survival at 5 years typically ranges between 50
and 70% [1, 3–10]. Most mortality is due to metastatic
disease, which occurs in approximately 30% of patients [8,
11, 12].
As EWS carries a guarded prognosis, much eﬀort has
beenmadetodiscoverprognosticfactors.Reliableprognostic
factors could identify particularly high-risk patients who
might beneﬁt from more aggressive treatment approaches
and perhaps even investigational agents. Among possible
prognostic factors, the presence of metastatic disease at the
time of diagnosis, large tumor volume, and poor response to
preoperative chemotherapy have been consistently shown to
confer a poor prognosis [2, 7–9, 11–16].
Unlike osteosarcoma which favors the femoral and tibial
metaphysis,EWSoccursinbothaxialandappendicularloca-
tions. In the Mayo Clinic series, approximately 44% of EWS
patientshadaxialdisease[17].Thep r ognosticimpo rtanc eo f
anatomic location (i.e., axial versus appendicular) is unclear.
Someauthorshavefoundanatomiclocationtobeprognostic
while others have not [1, 3, 6–9, 11–14, 18–23]. It is diﬃcult
to isolate the prognostic eﬀect of anatomic location from
other pretreatment variables such as tumor size and the
presence of metastatic disease. Preclinical research [24]h a s
suggested that axial location may be associated with a more2 Sarcoma
aggressive biological phenotype than appendicular EWS, but
this has not been validated or demonstrated in a clinical
setting.
The purpose of this study is to report a single institution
experience in the management of patients with bone and
soft tissue EWS, and to investigate the importance of
anatomiclocationasaprognosticfactor.Wehypothesizethat
axial location confers a worse prognosis than appendicular
location. We further hypothesize that axial location indepen-
dently predicts poor prognosis in EWS and may suggest a
biologic diﬀerence between axial and appendicular EWS.
2. Methods
2.1. Patients. After approval from our institutional research
ethics board, we searched our sarcoma database for all
patients with EWS treated consecutively between 1989 and
2007. A minimum of 2-year followup was required for
all patients. Seventy patients were identiﬁed. Three had
incomplete records and were excluded, leaving 67 patients
in the study group. Patients’ electronic records, paper
charts, and radiographs (when available) were reviewed.
Demographic data and details of treatment and clinical
course were collected.
Axial bone EWS was deﬁned as disease originating from
the spine, sacrum, pelvis, scapula, clavicle, or rib cage.
Appendicular bone EWS was deﬁned as disease originating
from any bone in the extremities. Axial soft tissue EWS was
deﬁned as originating in the head, neck, or torso. Appendic-
ular soft tissue EWS originated from the extremities.
(Thescapulaandclaviclewereincludedintheaxialgroup
because (1) they form via intramembranous ossiﬁcation, (2)
theirgeometryisclearlydiﬀerentthanthelongtubularbones
of the extremities, and (3) their location overlying the chest
wall is more central than the bones of the extremities.)
2.2. Staging and Treatment. Staging investigations at diagno-
sis included computed tomography (CT) scan of the chest
and total body bone scan. Some patients received total
body gallium scan, magnetic resonance imaging (MRI) of
the primary tumor, and bilateral bone marrow aspirations
and biopsies. Sixty-six (99%) patients received chemother-
apy consisting of vincristine, doxorubicin, and cyclophos-
phamide (total 5 cycles) alternating with etoposide and
ifosfamide (total 5 cycles) for a total of 10 planned treatment
cycles.
Deﬁnitive local treatment was by en bloc surgical resec-
tion whenever possible. XRT was used for lesions that were
unresectable,ortotreatpositiveresectionsmarginsfollowing
surgical management. Patients treated with deﬁnitive XRT
alone received 5000 centigrays (cGy) in 25 fractions to
the entire medullary cavity to cover radiographic bone
marrow changes plus a 2cm margin, followed by a boost
to 6000–6600cGy in 30–33 fractions. Similarly, patients
with microscopic residual disease postoperatively received
5000cGyin25fractionstothetumorbedplusa5cmmargin.
2.3. Statistical Analysis. The primary outcome measure was
overall survival considered from the date of diagnosis to the
date of death and estimated with the Kaplan-Meier method.
Patients who did not experience death over the study period
were censored.
Cox proportional hazard regression models were used to
estimate the eﬀect of diﬀerent variables on overall survival
[25]; proportional hazard assumptions were checked using
scaled Schoenfeld residuals [26]. The variables considered,
besides anatomic location, were tumor size, metastases at
diagnosis, treatment with radiation, and surgical margins. In
accordance with AJCC guidelines, tumor size was evaluated
as greater or less than 8cm in largest dimension for bone
EWS, and greater or less than 5cm for soft tissue EWS. First,
a univariate model was ﬁtted with anatomic location as the
sole predictor. If a signiﬁcant eﬀect of anatomic location was
shown,asecondmultivariatemodelwasﬁttedwithanatomic
location and pretreatment variables (size and metastases at
diagnosis). This second model would give us some insight
as to whether the observed eﬀect of anatomic location
could be explained partially by diﬀerences in pretreatment
variables. Last, a third multivariate model with anatomic
location, pretreatment variables, and treatment variables
(radiation and surgical margins) was ﬁtted to assess if some
eﬀect of anatomic location remained after adjusting for pre-
treatment and treatment-related variables. This last model
was only ﬁtted in patients who had undergone surgery.
Signiﬁcance was considered for P values ≤ 0.05; all tests were
two sided.
3. Results and Discussion
3.1. Results. Of the 67 patients, 41 were male and 26 were
female. The mean age at diagnosis was 26.9 years with a
range of 12.4–77.9 years. Fifty-seven (85%) patients had
bone EWS and 10 (15%) had soft tissue EWS. Thirty-four
(51%) patients had axial EWS and 33 (49%) patients had
appendicular EWS. The demographic, pre-treatment, and
treatment characteristics of the axial and appendicular EWS
groups are described in Table 1. Sixty-six (99%) patients
received chemotherapy, and 54 (81%) received deﬁnitive
local treatment with surgery and/or XRT. Margins for the 44
patients who had surgery were negative in 35 patients (80%)
and micro- or macroscopically positive in 9 patients (20%).
Of all variables, either pre-treatment or treatment, only the
status of surgical margins showed a noteworthy diﬀerence
with axial tumors more likely to be resected with positive
margins (6 of 16 compared to 3 of 28; P value = 0.053).
O v e r a l ls u r v i v a lf o rt h ew h o l eg r o u pw a s6 4 %a t2y e a r s
(95% conﬁdence interval: 53% to 77%), 47% at 5 years (95%
CI: 35% to 62%), and 44% at 10 years (95% CI: 32% to 60%,
Figure 1). Overall survival in patients with axial EWS was
44% at 2 years (95% CI: 30% to 66%), 29% at 5 years, (95%
CI:16%to52%),and29%at10years(95%CI:16%to52%).
Comparatively,overallsurvivalinpatientswithappendicular
EWS was 84% at 2 years (95% CI: 72% to 98%), 66% at
5 years, (95% CI: 50% to 88%), and 61% at 10 years (95%
CI: 43% to 84%). Overall survival was signiﬁcantly worse for
patients with axial EWS (P = 0.002, Figure 2).
Univariate analysis revealed that axial location (P =
0.002), large size (P = 0.003), the presence of metastases atSarcoma 3
Table 1: Patient Information. Table 1 depicts demographic data, pretreatment characteristics, and treatment characteristics for the axial
EWS and appendicular EWS groups.
Axial EWS (n = 34, 51%) Appendicular EWS (n = 33, 49%) Total (n = 67) P value
Pretreatment Factors
Median Age 25.1 28.7 26.9 0.23
No. male 21 (62%) 20 (61%) 41 (61%) 0.30
No. female 13 (38%) 13 (39%) 26 (39%) —
No. bone 31 (91%) 26 (79%) 57 (85%) 0.19
No. soft tissue (ST) 3 (9%) 7 (21%) 10 (15%) —
No. with metastases at diagnosis 10 (29%) 5 (15%) 15 (22%) 0.33
No. bone lesions over 8cm 21 (62%) 17 (52%) 38 (57%) 0.9
No. bone lesions under 8cm 10 (29%) 9 (27%) 19 (28%) —
No. ST lesions over 5cm 1 (3%) 4 (12%) 5 (7%) 1.0
No. ST lesions under 5cm 2 (6%) 3 (9%) 5 (7%) —
Treatment Factors
No. receiving deﬁnitive treatment 25 (74%) 29 (88%) 54 (81%) 0.22
No. receiving deﬁnitive surgery 16 (47%) 28 (85%) 44 (66%) 0.0018
No. receiving deﬁnitive XRT 9 (26%) 1 (3%) 10 (15%) 0.013
No. not receiving surgery or XRT 9 (26%) 4 (12%) 13 (19%) 0.22
No. receiving adjuvant XRT 8 (24%) 2 (6%) 10 (15%) 0.045
Outcome Parameters
No. positive margins 6 (18%) 3 (9%) 9 (13%) 0.0031
No. local recurrences 5 (15%) 0 (0%) 5 (7%) 0.053
No. ANED 10 (29%) 22 (67%) 32 (48%)
No. AWED 2 (6%) 1 (3%) 3 (4%)
No. DOD 22 (65%) 10 (30%) 32 (48%)
% 5-year OS 29% 66% 0.002
Table 2: Eﬀects of pre-treatment and treatment variables in
univariable Cox proportional hazard models.
Variable/model Univariate model
HR [95% CI] P value
Site (axial) 3.07 [1.44–6.52] 0.0022
Size (large) 3.8 [1.46–9.9] 0.0034
Metastasis (yes) 4.1 [1.99–8.43] <0.001
Radiation (yes) 1.53 [0.76–3.11] 0.23
Surgical margins (positive) 3.3 [1.04–10.43] 0.031
HR (hazard ratio); 95% CI (95% conﬁdence interval).
diagnosis (P<0.001), and positive margins (P = 0.031) all
predicted poor overall survival. Treatment with XRT was not
signiﬁcantlyassociatedwithworseoverallsurvival(P = 0.23,
Table 2). In the second model, after adjusting for the eﬀect of
pre-treatment variables, axial location remained associated
with decreased overall survival with a hazard ratio of 3.11
(95% CI: 1.41 to 6.84; P value = 0.005). In the third model,
after adjusting for pre-treatment and treatment variables,
axial location was associated with decreased overall survival
with a hazard ratio of 4.73 (95% CI: 0.87 to 25.7); however
thisassociationwasnotsigniﬁcant(P value =0.072,Table 3).
3.2. Discussion. EWS is a member of the “small round blue
cell” family of tumors along with rhabdomyosarcoma and
lymphoma of bone. It is thought to have a neuroectodermal
origin and is characterized by a genetic translocation t(11;
22)inover95%ofcases[27].Wehavecombinedourpatients
with bone and soft tissue EWS as it has been reported
that these two presentations of EWS are similar in terms
of genetics, histology, goals of treatment, and prognosis
[1, 2].
We found that axial location was predictive of worse
overall survival in univariate analysis, and in multivariate
analyses when adjusting for pre-treatment variables. Axial
skeletal location did not achieve statistical signiﬁcance when
adjusted for pre-treatment and treatment variables (P =
0.072) but the hazard ratio was still high (4.73). Argon et al.
(n = 25), Gupta et al. (n = 53), and Hense et al. (n = 945)
found that anatomic location correlated with poor outcome
[3,11,13].Henseetal.,inparticular,suggestedthatanatomic
location may be more prognostically important than tumor
volume. Lee et al. [7] in their series of 725 patients from the
California Cancer Registry reported that pelvic site predicted
poor overall survival in univariate, but not multivariate
analysis.Wespeciﬁcallyattemptedtoisolatethecontribution
of anatomic location to overall survival by adjusting for pre-
treatment (model 2) and treatment (model 3) factors. The
fact that the hazard ratio did not vary much between models
1, 2, and 3 suggests that the worse prognosis associated with
axial location is explained neither by pre-treatment variables
nortreatmentvariables.However,cautioniswarrantedasthe4 Sarcoma
Table 3: Eﬀect of anatomic location in univariable (model 1), multivariable analysis when adjusting for pre-treatment variables (model 2),
and when adjusting for pre-treatment and treatment variables (model 3).
Variable/model Model 1 Model 2 Model 3
HR [95% CI] P value HR [95% CI] P value HR [95% CI] P value
Site (axial) 3.07 [1.44–6.52] 0.0022 3.11 [1.41–6.84] 0.0048 4.73 [0.87–25.74] 0.072
Size (large) — — 3.85 [1.44–10.32] 0.0072 4.35 [0.78–24.34] 0.094
Metastasis (yes) — — 2.9 [1.37–6.13] 0.0055 2.99 [0.31–5.01] 0.34
Radiation (yes) — — — — 0.79 [0.13–5.01] 0.81
Surgical margins (positive) — — — — 2.47 [0.63–9.63] 0.19
HR (hazard ratio); 95% CI (95% conﬁdence interval).
0 50 100 150 200
0
0.2
0.4
0.6
0.8
1
Time (months)
S
u
r
v
i
v
a
l
p
r
o
b
a
b
i
l
i
t
y
Figure 1: Overall survival, all patients. Figure 1 displays overall
survival for all 67 patients. Overall survival was 47% (95% CI =
0.35–0.62) at 5 years and 44% (95% CI = 0.32–0.60) at 10 years.
sample size was relatively small and only a limited number of
other variables were included in the models.
There were essentially equal proportions of large and
small tumors in the axial and appendicular groups by AJCC
criteria. It has been widely assumed that the reason for the
worse prognosis of axial EWS is because these tumors are
larger than those located in the appendicular skeleton. This
was not the case in our study population, and our ﬁndings
suggest that size alone does not explain the diﬀerence in
prognosis between axial and appendicular EWS.
There was indeed a modicum of treatment heterogeneity.
The axial and appendicular groups had diﬀerent proportions
of patients who received surgery (47% versus 85%), who had
positive surgical margins (38% versus 10%), and who were
treated with deﬁnitive XRT (27% versus 3%). It is entirely
possible that these treatment diﬀerences contributed to the
outcome of the axial and appendicular groups.
Hense et al. [11] described an unexplained, intrinsic
quality to axial tumors. They postulated that the pelvis
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Figure 2: Overall survival, axial versus appendicular. Figure 2
depicts overall survival as a function of anatomic location. Overall
survival for the axial group was 29% (95% CI = 0.16–0.52) at 5
years and 10 years. Overall survival was 66% (95% CI = 0.50–0.88)
at 5 years and 61% (95% CI = 0.43–0.84) at 10 years. The diﬀerence
in overall survival between the 2 groups was statistically signiﬁcant
(P = 0.002).
posseses “...an additional eﬀect that appears speciﬁc to
the pelvic site and that was not explained by the variables
considered in our statistical analyses. Our study falls short
of providing any further clues as to what may constitute this
speciﬁc feature of pelvic lesions.” We propose that axial EWS
m a yb eb i o l o g i c a l l yd i ﬀerent from appendicular EWS. For
example, in a series of Ewing’s sarcoma of the foot and ankle
by San-Julian et al., overall survival was 93% [28], which
is extraordinarily high. Weiss et al. suggested that axial and
appendicular EWS behave diﬀerently in an animal model of
EWS. Experimental animals were orthotopically implanted
with EWS tumor fragments in the leg or the chest wall. Chest
wall tumors grew much more reproducibly and aggressively
than leg tumors [24]. These data may collectively suggestSarcoma 5
biologic diﬀerences between axial and appendicular EWS
that ultimately result in prognostic diﬀerences.
4. Conclusions
In conclusion, in our study population axial location
predicted poor prognosis in EWS. This risk remains after
adjusting for pre-treatment and treatment variables. Axial
EWS may therefore possess a more aggressive phenotype
by virtue of the microenvironmental milieu of the axial
skeleton, and the interaction between EWS cells and this
microenvironment. Additional clinical and basic scientiﬁc
investigations will help to prove or disprove this hypothesis.
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